On May 14, 2024, Kura Oncology, Inc. announced that it completed enrollment of 85 patients in the Phase 2 portion of KOMET-001, a registration-directed clinical trial of the Company's menin inhibitor, ziftomenib (KO-539), in patients with relapsed or refractory NPM1-mutant acute myeloid leukemia. The Company expects to report topline data from the trial in early 2025.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
20.94 USD | +3.05% |
|
+0.58% | +45.62% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+45.62% | 159.52Cr | |
+15.19% | 12TCr | |
+19.91% | 11TCr | |
+8.24% | 2.36TCr | |
-19.80% | 2.04TCr | |
-16.19% | 1.65TCr | |
-13.45% | 1.64TCr | |
-44.35% | 1.56TCr | |
+66.67% | 1.52TCr | |
+2.13% | 1.35TCr |
- Stock Market
- Equities
- KURA Stock
- News Kura Oncology, Inc.
- Kura Oncology, Inc. Completes Enrollment of 85 Patients in the Phase 2 Portion of KOMET-001